Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Victoria M. Garbitt"'
Autor:
Arianna Calcinotto, Arianna Brevi, Marta Chesi, Roberto Ferrarese, Laura Garcia Perez, Matteo Grioni, Shaji Kumar, Victoria M. Garbitt, Meaghen E. Sharik, Kimberly J. Henderson, Giovanni Tonon, Michio Tomura, Yoshihiro Miwa, Enric Esplugues, Richard A. Flavell, Samuel Huber, Filippo Canducci, Vincent S. Rajkumar, P. Leif Bergsagel, Matteo Bellone
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
The mechanisms through which gut microbiota affect extramucosal tumors are poorly understood. Here the authors show that the gut microbiota promotes multiple myeloma by inducing differentiation and migration of Th17 cells in the bone marrow resulting
Externí odkaz:
https://doaj.org/article/6dd882c727de4bf2854877a2bb52782e
Autor:
Marta Chesi, Caleb K. Stein, Shaji Kumar, Seth J. Welsh, Yan W. Asmann, P. Leif Bergsagel, Daniel L. Riggs, Erin W. Meermeier, Esteban Braggio, Meaghen E. Sharik, Victoria M. Garbitt, Matteo Bergsagel
Publikováno v:
Blood Cancer Discov
The most common genetic abnormality in multiple myeloma is the deletion of chromosome 13, seen in almost half of newly diagnosed patients. Unlike chronic lymphocytic leukemia, where a recurrent minimally deleted region including MIR15A/MIR16-1 has be
Autor:
Pavel Strop, P. Leif Bergsagel, Marta Chesi, Megan T. Du, Matthew L. Wheeler, Bryant Chau, Victoria M. Garbitt, Marco Bergsagel, Natalie Bezman, Caleb K. Stein, Chang-Xin Shi, Meaghen E. Sharik, Feng Wang, Daniel L. Riggs, Erin W. Meermeier, Seth J. Welsh
Publikováno v:
Blood Cancer Discov
BCMA/CD3-targeting bispecific antibodies (BsAb) are a recently developed immunotherapy class that shows potent tumor killing activity in multiple myeloma. Here, we investigated a murine BCMA/CD3-targeting BsAb in the immunocompetent Vk*MYC model and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb9f36adc448e13bc6a0a5e8f268bc3
https://europepmc.org/articles/PMC8266040/
https://europepmc.org/articles/PMC8266040/
Autor:
Megan Du, Lawrence H. Boise, P. Leif Bergsagel, Sochilt Brown, Chang-Xin Shi, Meaghen E. Sharik, Marta Chesi, Kennedi T. Todd, Victoria M. Garbitt, Benjamin G. Barwick, Zachary J. Hammond, Caleb K. Stein, Paola Neri, Nizar J. Bahlis, Daniel L. Riggs, Erin W. Meermeier, Seth J. Welsh, W. Michael Kuehl
Publikováno v:
Blood. 138:1593-1593
Multiple myeloma (MM) is an incurable form of plasma cell cancer in which primary and secondary chromosomal translocations routinely juxtapose oncogenes to plasma cell-specific super-enhancers. Coincidentally, drugs which target super-enhancers have
Autor:
Sochilt Brown, Marco Bergsagel, Marta Chesi, P. Leif Bergsagel, Victoria M. Garbitt, Erin W. Meermeier, Kennedi T. Todd, Caleb K. Stein, Meaghen E. Sharik, Seth J. Welsh
Publikováno v:
Cancer Research. 80:5630-5630
BCMA is an ideal target antigen for myeloma immunotherapy as it is specifically expressed by plasma cells and T cell-engaging, BCMA-bispecific antibodies show potent tumor killing activity in human multiple myeloma (MM). However, a lack of longevity,
Autor:
Marta Chesi, Meaghen E. Sharik, Nicholas E. Banovich, Seth J. Welsh, P. Leif Bergsagel, Jonathan J Keats, Victoria M. Garbitt, Caleb K. Stein, Erin W. Meermeier
Publikováno v:
Cancer Research. 80:5622-5622
Previously, the IAP antagonist LCL161 was shown to have robust anti-myeloma activity in a transgenic mouse model where an acute inflammatory response accompanied a reduction in tumor burden. In order to fully examine alterations to the immune microen
Autor:
Daniel L. Riggs, Jonathan J Keats, Victoria M. Garbitt, P L Bergsagel, S Van Wier, K Tamizhmani, Yulia N. Demchenko, Leslie A. Brents, A V Roschke, W. M. Kuehl, Maurizio Affer, W D Chen, Marta Chesi, R Fonseca
Publikováno v:
Leukemia
MYC locus rearrangements-often complex combinations of translocations, insertions, deletions and inversions-in multiple myeloma (MM) were thought to be a late progression event, which often did not involve immunoglobulin genes. Yet, germinal center a
Autor:
Yan W. Asmann, Craig B. Reeder, P. Leif Bergsagel, Asher Chanan-Khan, Gregory J. Ahmann, Angela Dispenzieri, Kevin M Morrison, Marta Chesi, Morie A. Gertz, Noweeda Mirza, Yi Lin, Meaghen E. Sharik, Sikander Ailawadhi, Victoria M. Garbitt, Francis K. Buadi, Arianna Calcinotto, Daniel L. Riggs, Amylou C. Dueck, Ilseyar Akhmetzyanova, David Dingli, Martha Q. Lacy, Rafael Fonseca, Shaji Kumar, A. Keith Stewart, David R. Fooksman, Heidi E. Kosiorek, Niamh Keane
The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e27f5483b79ae7a7731004a7d8c981
https://europepmc.org/articles/PMC5515246/
https://europepmc.org/articles/PMC5515246/
Autor:
Daniel L. Riggs, Camille Herzog, Victoria M. Garbitt, Niamh Keane, Courtney J. Hillukka, Zachary J. Hammond, Julia E. Wiedmeier, Seth J. Welsh, Shulan Tian, Huihuang Yan, Ranjan Maity, Nizar Bahlis, Paola Neri, W Michael Kuehl, Marta Chesi, P Leif Bergsagel
Publikováno v:
Cancer Research. 79:3015-3015
MYC dysregulation, the most common genetic aberration in multiple myeloma, is frequently due to the translocation of super-enhancers to the MYC locus. Several drugs target proteins that are enriched at many of these enhancers including BRD4 (BET inhi
Autor:
Seth J. Welsh, Meaghen E. Sharik, Victoria M. Garbitt, Link R. Taylor, Daniel L. Riggs, Caleb Stein, Grady Day, Courtney J. Hillukka, Zach J. Hammond, P Leif Bergsagel, Marta Chesi
Publikováno v:
Cancer Research. 79:4628-4628
Multiple myeloma (MM) is a predominantly incurable form of plasma cell cancer. Although immunomodulatory imide drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide constitute the backbone of most MM therapies, little is understood about